Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

D Norris

Showing results (391-400 of 531) with videos related to

Pageof 54
Sort By:
Journal of Community Health|March 31, 2023
Application Status Among Women Enrolled in a Healthy Start Program in Arkansas for the Special Nutrition Program for Women and ChildrenSharon Reece, Pearl A McElfish, Jennifer A Andersen, et al.
Hormones & Cancer|February 15, 2017
MMTV-PyMT and Derived Met-1 Mouse Mammary Tumor Cells as Models for Studying the Role of the Androgen Receptor in Triple-Negative Breast Cancer ProgressionJessica L Christenson, Kiel T Butterfield, Nicole S Spoelstra, et al.
Molecular Cancer Therapeutics|April 14, 2005
Expression of multidrug transporter MRP4/ABCC4 is a marker of poor prognosis in neuroblastoma and confers resistance to irinotecan in vitroMurray D Norris, Janice Smith, Kara Tanabe, et al.
Proceedings of the National Academy of Sciences of the United States of America|November 30, 2022
Inflammatory response to retrotransposons drives tumor drug resistance that can be prevented by reverse transcriptase inhibitorsKsenia A Novototskaya-Vlasova, Nickolay S Neznanov, Ivan Molodtsov, et al.
British Journal of Haematology|June 9, 2009
Clinical significance of minimal residual disease at day 15 and at the end of therapy in childhood acute lymphoblastic leukaemiaRosemary Sutton, Nicola C Venn, Jonathan Tolisano, et al.
Biochemical Pharmacology|July 15, 2019
MRP1 modulators synergize with buthionine sulfoximine to exploit collateral sensitivity and selectively kill MRP1-expressing cancer cellsChristine C Gana, Kimberley M Hanssen, Denise M T Yu, et al.
Cancer Immunology, Immunotherapy : CII|April 4, 2008
Induction of T cell-mediated immunity using a c-Myb DNA vaccine in a mouse model of colon cancerBenjamin B Williams, Meg Wall, Rebecca Yu Miao, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 15, 2003
Importance of minimal residual disease testing during the second year of therapy for children with acute lymphoblastic leukemiaGlenn M Marshall, Michelle Haber, Edward Kwan, et al.
Endocrinology|September 1, 1997
Dissection of the molecular mechanism of action of GW5638, a novel estrogen receptor ligand, provides insights into the role of estrogen receptor in boneT M Willson, J D Norris, B L Wagner, et al.
Oncotarget|June 23, 2014
Histone deacetylase 2 and N-Myc reduce p53 protein phosphorylation at serine 46 by repressing gene transcription of tumor protein 53-induced nuclear protein 1Jeyran Shahbazi, Christopher J Scarlett, Murray D Norris, et al.
Pageof 54

Showing results (391-400 of 531) with videos related to

Sort By:
Pageof 54
Journal of Community Health|March 31, 2023
Application Status Among Women Enrolled in a Healthy Start Program in Arkansas for the Special Nutrition Program for Women and ChildrenSharon Reece, Pearl A McElfish, Jennifer A Andersen, et al.
Hormones & Cancer|February 15, 2017
MMTV-PyMT and Derived Met-1 Mouse Mammary Tumor Cells as Models for Studying the Role of the Androgen Receptor in Triple-Negative Breast Cancer ProgressionJessica L Christenson, Kiel T Butterfield, Nicole S Spoelstra, et al.
Molecular Cancer Therapeutics|April 14, 2005
Expression of multidrug transporter MRP4/ABCC4 is a marker of poor prognosis in neuroblastoma and confers resistance to irinotecan in vitroMurray D Norris, Janice Smith, Kara Tanabe, et al.
Proceedings of the National Academy of Sciences of the United States of America|November 30, 2022
Inflammatory response to retrotransposons drives tumor drug resistance that can be prevented by reverse transcriptase inhibitorsKsenia A Novototskaya-Vlasova, Nickolay S Neznanov, Ivan Molodtsov, et al.
British Journal of Haematology|June 9, 2009
Clinical significance of minimal residual disease at day 15 and at the end of therapy in childhood acute lymphoblastic leukaemiaRosemary Sutton, Nicola C Venn, Jonathan Tolisano, et al.
Biochemical Pharmacology|July 15, 2019
MRP1 modulators synergize with buthionine sulfoximine to exploit collateral sensitivity and selectively kill MRP1-expressing cancer cellsChristine C Gana, Kimberley M Hanssen, Denise M T Yu, et al.
Cancer Immunology, Immunotherapy : CII|April 4, 2008
Induction of T cell-mediated immunity using a c-Myb DNA vaccine in a mouse model of colon cancerBenjamin B Williams, Meg Wall, Rebecca Yu Miao, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 15, 2003
Importance of minimal residual disease testing during the second year of therapy for children with acute lymphoblastic leukemiaGlenn M Marshall, Michelle Haber, Edward Kwan, et al.
Endocrinology|September 1, 1997
Dissection of the molecular mechanism of action of GW5638, a novel estrogen receptor ligand, provides insights into the role of estrogen receptor in boneT M Willson, J D Norris, B L Wagner, et al.
Oncotarget|June 23, 2014
Histone deacetylase 2 and N-Myc reduce p53 protein phosphorylation at serine 46 by repressing gene transcription of tumor protein 53-induced nuclear protein 1Jeyran Shahbazi, Christopher J Scarlett, Murray D Norris, et al.
Pageof 54